Core Insights - MBX Biosciences is advancing its clinical programs, particularly focusing on canvuparatide for chronic hypoparathyroidism and MBX 4291 for obesity, with significant milestones expected in 2026 [2][4] Group 1: Clinical Development - The Phase 2 trial of canvuparatide has shown strong proof-of-concept with high responder rates and is preparing for a pivotal Phase 3 trial set to initiate in Q3 2026 [4] - One-year follow-up data from the Phase 2 trial of canvuparatide is anticipated in Q2 2026, which will provide further insights into its efficacy [1] - MBX 4291, a dual GLP-1/GIP co-agonist prodrug, is progressing through Phase 1 evaluation, with 12-week data expected in Q4 2026 [1][4] Group 2: Pipeline Expansion - The company plans to nominate two additional obesity candidates in 2026, including an amycretin prodrug and a GLP-1/GIP/GCGR triple agonist, both designed for once-monthly dosing [1][4] - Results from the ongoing Phase 2a STEADI™ trial of imapextide are expected in Q2 2026, focusing on post-prandial glucose regulation [4] Group 3: Financial Position - As of December 31, 2025, MBX Biosciences reported a preliminary unaudited cash position of approximately $373.7 million, which is expected to fund operations into 2029 [5][6] - The strong cash position allows the company to continue investing in long-term pipeline growth and execute its strategic plans effectively [2]
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference